Results 21 to 30 of about 3,389 (131)
ABSTRACT The Clinical and Laboratory Standards Institute M100 document serves as a cornerstone standard for clinical microbiology laboratories in China. Maintaining the scientific rigor of its predecessors, the 36th edition incorporates updated epidemiological cutoff values, pharmacokinetic/pharmacodynamic data, and clinical efficacy evidence to revise
Kanghong Xu, Qi Wang, Hui Wang
wiley +1 more source
AmpC β-lactamase induction by avibactam and relebactam [PDF]
Background: Diazabicyclooctanes, e.g. avibactam and relebactam, are a new class of β-lactamase inhibitors. Their spectrum includes AmpC enzymes, but it is important to understand whether they also induce these enzymes.
Neil Woodford +11 more
core +1 more source
ABSTRACT Ceftazidime/avibactam (CAZ‐AVI) is an important therapeutic option for multidrug‐resistant (MDR) Pseudomonas aeruginosa infections; however, hypersensitivity reactions may preclude its use and create significant therapeutic challenges. We report a 21‐year‐old woman with cystic fibrosis and recurrent MDR P.
Zuoren Zhou +6 more
wiley +1 more source
ABSTRACT Pan‐drug resistant Klebsiella pneumoniae is a major therapeutic challenge, particularly when standard last‐line agents are unavailable or contraindicated. We report a 45‐year‐old man with multifocal osteomyelitis and persistent purulent wound discharge despite broad‐spectrum antibiotics, repeated debridement, and two sequential amputations ...
Ali Akbar Heydari +2 more
wiley +1 more source
Novel KPC‐25 and first‐reported KPC‐127 sequentially evolved in one patient under CAZ‐AVI pressure, distinct mutations remodel enzyme activity to drive differential multidrug resistance. ABSTRACT The emergence of novel Klebsiella pneumoniae carbapenemase (KPC) variants contributing to clinical treatment failure poses a substantial threat to public ...
Ke Lei +8 more
wiley +1 more source
Background: Pseudomonas aeruginosa shows resistance to several antibiotics and often develops such resistance during patient treatment. Objective: Develop an in vitro model, using clinical isolates of P. aeruginosa, to compare the ability of the imipenem
Esperanza Merino +8 more
core +1 more source
Phage therapy shows promising efficacy against MDR, XDR, and PDR Pseudomonas aeruginosa infections across different models and administration routes. Evidence highlights reduced mortality, bacterial clearance, and synergy with antibiotics, while emphasizing the need for standardized protocols and advanced delivery systems to support clinical ...
Gustavo Aparecido da Cunha +7 more
wiley +1 more source
This review describes how an integrated structural biology platform at Merck Sharp & Dohme LLC, Rahway, New Jersey, USA, combining X‐ray crystallography, cryo‐EM, MicroED and cryo‐ET, enables seamless three‐dimensional insights from molecular to cellular length scales.
Jill E. Chrencik +44 more
wiley +1 more source
ABSTRACT Nacubactam is a β‐lactamase inhibitor. Early‐phase studies with 1000/2000/4000/8000 mg nacubactam monotherapy were not powered to assess proarrhythmic risk. Therefore, this analysis pooled electrocardiogram data from two placebo‐controlled studies to quantify potential effects of nacubactam on cardiac repolarization.
Jun Morita, Sue McKendrick, Yuji Kumagai
wiley +1 more source
Early Multicenter Experience With Imipenem-Cilastatin-Relebactam for Multidrug-Resistant Gram-Negative Infections [PDF]
A multicenter case series of 21 patients were treated with imipenem-cilastatin-relebactam. There were mixed infection sources, with pulmonary infections (11/21,52%) composing the majority. The primary pathogen was Pseudomonas aeruginosa (16/21, 76%), and
Lagnf, Abdalhamid M. +19 more
core +1 more source

